MX2008002161A - Chimeric antibodies with new world primate regions. - Google Patents

Chimeric antibodies with new world primate regions.

Info

Publication number
MX2008002161A
MX2008002161A MX2008002161A MX2008002161A MX2008002161A MX 2008002161 A MX2008002161 A MX 2008002161A MX 2008002161 A MX2008002161 A MX 2008002161A MX 2008002161 A MX2008002161 A MX 2008002161A MX 2008002161 A MX2008002161 A MX 2008002161A
Authority
MX
Mexico
Prior art keywords
regions
new world
chimeric antibodies
world primate
cdr
Prior art date
Application number
MX2008002161A
Other languages
Spanish (es)
Inventor
Philip Anthony Jennings
Anthony Gerard Doyle
Adam William Clarke
Original Assignee
Arana Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005904406A external-priority patent/AU2005904406A0/en
Application filed by Arana Therapeutics Ltd filed Critical Arana Therapeutics Ltd
Publication of MX2008002161A publication Critical patent/MX2008002161A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

The present invention provides a chimeric antibody or an antigen-binding portion thereof. The antigen-binding portion comprises at least two complementarity determining regions (CDR) and at least three framework regions, wherein at least one CDR is a New World primate CDR.
MX2008002161A 2005-08-15 2006-08-15 Chimeric antibodies with new world primate regions. MX2008002161A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005904406A AU2005904406A0 (en) 2005-08-15 New World Antibodies
PCT/AU2006/001166 WO2007019621A1 (en) 2005-08-15 2006-08-15 Chimeric antibodies with new world primate regions

Publications (1)

Publication Number Publication Date
MX2008002161A true MX2008002161A (en) 2008-04-22

Family

ID=37757238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008002161A MX2008002161A (en) 2005-08-15 2006-08-15 Chimeric antibodies with new world primate regions.

Country Status (13)

Country Link
EP (1) EP1945669A4 (en)
JP (1) JP2009504686A (en)
KR (1) KR20080068005A (en)
CN (2) CN101287762A (en)
AU (1) AU2006281981A1 (en)
BR (2) BRPI0614430A2 (en)
CA (1) CA2619245A1 (en)
MX (1) MX2008002161A (en)
NO (1) NO20080800L (en)
NZ (1) NZ565904A (en)
RU (1) RU2008110058A (en)
WO (1) WO2007019621A1 (en)
ZA (2) ZA200802246B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2575838A1 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
CN101400703B (en) 2006-02-01 2013-05-08 赛法隆澳大利亚控股有限公司 Domain antibody construct
JP5721951B2 (en) * 2007-03-22 2015-05-20 バイオジェン アイデック マサチューセッツ インコーポレイテッド Binding proteins that specifically bind to CD154, including antibodies, antibody derivatives, and antibody fragments, and uses thereof
WO2010017595A1 (en) * 2008-08-14 2010-02-18 Arana Therapeutics Limited Variant domain antibodies
RU2535034C2 (en) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Medication and method of preventing hiv infection, prevention and treatment of hiv-induced or hiv-associated diseases, including aids
RU2535033C2 (en) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Therapeutic agent and method for prevention of hiv infection and treatment of hiv-caused or hiv-associated diseases, including aids
RU2577299C2 (en) * 2011-07-04 2016-03-10 Олег Ильич Эпштейн Method for treating infectious diseases and complex medication for treatment of infectious diseases
RU2521392C2 (en) * 2010-08-06 2014-06-27 Олег Ильич Эпштейн Combined drug for treating viral infections and method of treating viral infections
RU2516931C2 (en) * 2010-08-06 2014-05-20 Олег Ильич Эпштейн Method and composition for preventing hiv infection, preventing and treating hiv-caused or hiv-associated diseases, including aids
RU2517085C2 (en) * 2010-08-06 2014-05-27 Олег Ильич Эпштейн Complex medication and method of preventing hiv infection, prevention and treatment of hiv-induced and hiv-associated diseases, including aids
RU2502521C2 (en) * 2010-08-06 2013-12-27 Олег Ильич Эпштейн Combined drug for treating bacterial infections and method of treating bacterial infections
RU2519862C2 (en) * 2010-08-06 2014-06-20 Олег Ильич Эпштейн Complex medication and method of prevention and treatment of infectious viral diseases
RU2505312C2 (en) * 2010-08-06 2014-01-27 Олег Ильич Эпштейн Combined therapeutic agent for treating various types of influenza
RU2579262C1 (en) * 2014-10-02 2016-04-10 Мапикс Эс.Эй.Ар.Эл. Medicinal agent for treating infectious diseases
CL2015002152A1 (en) * 2015-07-31 2016-06-03 Pontificia Universidad Católica De Chile Monoclonal antibodies specific for the human syncytial respiratory virus (vrsh) antigen, produced and secreted by cellular hybridomas, useful for the detection and diagnosis of infection caused by vrsh

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605442B1 (en) * 1991-07-25 2003-04-16 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US6569431B2 (en) * 2000-10-17 2003-05-27 The Regents Of The University Of California Recombinant antibody fragments as autoantibody antagonists
US7235643B2 (en) * 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
CN1678634A (en) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 Immunoglobulin single variable antigen combination area and its opposite constituent
US20070212301A1 (en) * 2003-11-07 2007-09-13 Amgen, Inc. Monkey Immunoglobulin Sequences

Also Published As

Publication number Publication date
EP1945669A4 (en) 2009-07-22
WO2007019621A1 (en) 2007-02-22
BRPI0614867A2 (en) 2012-01-31
NZ565904A (en) 2012-02-24
ZA200802246B (en) 2009-09-30
JP2009504686A (en) 2009-02-05
RU2008110058A (en) 2009-09-27
BRPI0614430A2 (en) 2011-03-29
CA2619245A1 (en) 2007-02-22
ZA200802247B (en) 2009-08-26
NO20080800L (en) 2008-05-09
CN101287763A (en) 2008-10-15
EP1945669A1 (en) 2008-07-23
CN101287762A (en) 2008-10-15
KR20080068005A (en) 2008-07-22
AU2006281981A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
MX2008002161A (en) Chimeric antibodies with new world primate regions.
WO2007019620A8 (en) Engineered antibodies with new world primate framework regions
IL212949A0 (en) Humanized anti-cd4 antibody capable of activating cd4+ cd25+ regulatory t celle
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
ATE452147T1 (en) ANTIBODIES WITH CORRECTED CDR
WO2006096491A3 (en) Anti-ctla-4 antibody compositions
NZ602294A (en) Monoclonal antibodies against c-met
IL191217A (en) Humanized monoclonal anti-il-17 antibodies
WO2006031653A3 (en) Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
WO2007008943A3 (en) Optimized anti-ep-cam antibodies
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
WO2007120334A3 (en) Methods and compositions for targeting polyubiquitin
WO2008048970A8 (en) Synthetic antibodies
EP1761566A4 (en) Humanized anti-tag-72 monoclonal antibodies
HK1139697A1 (en) Humanized anti-ngf antibodies
RS53120B (en) Antagonistic human light-specific human monoclonal antibodies
WO2006039258A3 (en) Human antibodies against parathyroid hormone
EP2000541A4 (en) Humanized anti-cd20 monoclonal antibody
WO2007149932A3 (en) Methods and compositions for targeting hepsin
WO2008052108A3 (en) Methods for use in human-adapting monoclonal antibodies
WO2008110914A3 (en) Methods for producing active scfv antibodies and libraries therefor
EP1922412A4 (en) Humanized antibody conjugates and related methods, assays, reagents, and kits
WO2007002525A3 (en) Tomoregulin antibodies and uses thereof
WO2007002096A3 (en) Methods and compositions for targeting ifnar2
UA98100C2 (en) Humanized monoclonal antibody that binds and neutralizes human nogo

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FA Abandonment or withdrawal